Montelukast use over the past 20 years: monitoring of its effects and safety issues
Open Access
- 15 October 2020
- journal article
- review article
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 63 (10) , 376-381
Abstract
Montelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is recommended as an alternative treatment for asthma in children with mild persistent symptoms or as an add-on treatment to existing low-dose inhaled corticosteroids (ICSs) in children who require additional treatment. However, in the real-world setting, many doctors and patients prefer montelukast over ICSs despite their lower efficacy. Although montelukast is considered to be a safe drug, there are concerns regarding adverse drug reactions, including the rare occurrence of Churg-Strauss syndrome and, despite insufficient data, the possibility of neuropsychiatric events such as anxiety, depression, sleep disturbance, and suicidality. This review identified that montelukast has significantly contributed to asthma control over the past 20 years in Korea and has been critical for reducing asthma severity, especially early wheezing and disease control. Our findings suggest that the effects of montelukast treatment can be monitored by measuring serum eosinophilderived neurotoxin levels.Keywords
This publication has 51 references indexed in Scilit:
- Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthmaKorean Journal of Pediatrics, 2013
- Leukotrienes and airway inflammationBiochimica et Biophysica Acta (BBA) - General Subjects, 2011
- Eosinophil-Derived Neurotoxin in Childhood Asthma: Correlation With Disease SeverityJournal of Asthma, 2010
- Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children2010
- Safety and tolerability of montelukast in placebo‐controlled pediatric studies and their open‐label extensionsPediatric Pulmonology, 2009
- Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approachEuropean Respiratory Journal, 2008
- The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover studyThorax, 2008
- Cysteinyl leukotriene receptorsProstaglandins & Other Lipid Mediators, 2002
- SRS‐A leukotrienes decrease the activity of human respiratory ciliaClinical & Experimental Allergy, 1987
- Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response.Proceedings of the National Academy of Sciences, 1981